Published • loading... • Updated
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
The Phase III trial compared ivonescimab plus chemotherapy with durvalumab plus chemotherapy, and Akeso said nearly 30 studies will be presented at ESMO 2026.
- Akeso announced Monday that nearly 30 clinical studies of its bispecific antibodies will be presented at the 2026 European Society for Medical Oncology Congress in Madrid, Spain, October 23–27.
- Founded in 2012, Akeso maintains a pipeline of more than 50 innovative assets leveraging proprietary Tetrabody antibody technology and AI-powered drug research systems across its fully integrated platform.
- Positive overall survival results from the Phase III HARMONi-GI1 trial evaluating Ivonescimab plus chemotherapy for advanced biliary tract cancer were selected as a "Late-Breaking Abstract" for the Presidential Symposium.
- Ivonescimab will feature in 12 presentations at ESMO, while Cadonilimab, the world's first PD-1/CTLA-4 bispecific antibody, appears in 15 presentations covering more than ten tumor types including gastric and lung cancer.
- Researchers will deliver these findings throughout the Congress, reflecting Akeso's commitment to advancing next-generation immuno-oncology therapies and building a differentiated global oncology portfolio through breakthrough innovation.
Insights by Ground AI
12 Articles
12 Articles
Appalachian News-Express+11 Reposted by 11 other sources
Ivonescimab First-Line Biliary Tract Cancer Phase III Overall Survival Data Selected as ESMO Late-Breaking Abstract; Nearly 30 Akeso Studies to Be Presented at ESMO 2026
HONG KONG, Sept. 21, 2026 /PRNewswire/ -- Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that nearly 30 clinical studies of its globally first-in-class bispecific antibodies will be presented at the 2026 European Society for Medical Oncology (ESMO) Congress, taking…
Coverage Details
Total News Sources12
Leaning Left2Leaning Right1Center8Last UpdatedBias Distribution73% Center
Bias Distribution
- 73% of the sources are Center
73% Center
L 18%
C 73%
Factuality
To view factuality data please Upgrade to Premium
